Neurogene (NGNE) Provides Update on NGN-401 Gene Therapy Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Neurogene (NGNE) PT Lowered to $45 at BMO Capital
November 19, 2024 4:02 PM ESTBMO Capital analyst Keith Tapper lowered the price target on Neurogene (NASDAQ: NGNE) to $45.00 (from $60.00) while maintaining a Outperform rating.
The analyst comments "Neurogene shares are trading near cash on: 1) emerging SAE in a high-dose patient, consistent with overexposure/overdose of AAV9 or adenovirus... More
